Corvus Pharmaceuticals (CRVS) Net Loss Doubles to $8M in Q2 2025
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, dedicated to pioneering…
Browsing Tag